Jeff Wren - UCB SA President
UCBJY Stock | USD 58.22 1.22 2.14% |
President
Mr. Jeff Wren has served as Executive Vice President, Neurology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined the Company in October 2010. In his current role, he heads UCBs neurology patient value unit, neurology being one of UCBs two main therapy areas. He is responsible for the entire value chain of UCBs neurology portfolio, from development through medical, market access, sales and marketing. Before taking on his current role he was Senior Vice President UCB North America. He was responsible for providing leadership and strategic direction to all aspects of the organizations operations in both the US and Canada. Prior to this he was Vice President of UCBs Managed Markets and Trade Relations in the US and head of UCBs Canada operations. He was appointed as the Chairman of the Board for UCB, Inc. in the US as well as UCB Canada. He is member of the board of directors for BIO International. He was also appointed as Vicechair and executive committee member for Georgia Bio association group and member of the board of advisors for the Metro Atlanta Chamber of Commerce. He holds BS in Biology from Missouri Southern State University, Joplin, Missouri. At INSEAD he also completed Executive Business Program. since 2015.
Age | 55 |
Tenure | 9 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Michael Partridge | Vertex Pharmaceuticals | N/A | |
Daniel Plew | Regeneron Pharmaceuticals | 51 | |
Michael Aberman | Regeneron Pharmaceuticals | 45 | |
Bob Whelan | Pearson PLC ADR | 71 | |
Peter Ankersen | Novo Nordisk AS | N/A | |
Douglas McCorkle | Regeneron Pharmaceuticals | 58 | |
Kaare Schultz | Novo Nordisk AS | 52 | |
Jeffrey Chodakewitz | Vertex Pharmaceuticals | 60 | |
Jesper Brandgaard | Novo Nordisk AS | 54 | |
Charles Milstein | Vertex Pharmaceuticals | 42 | |
Kevin Capitani | Pearson PLC ADR | N/A | |
Maziar Doustdar | Novo Nordisk AS | 54 | |
Marion McCourt | Regeneron Pharmaceuticals | 64 | |
Kasper Poulsen | Novo Nordisk AS | N/A | |
Camilla Sylvest | Novo Nordisk AS | 52 | |
Peter Powchik | Regeneron Pharmaceuticals | 59 | |
George Yancopoulos | Regeneron Pharmaceuticals | 58 | |
Thomas Graney | Vertex Pharmaceuticals | 52 | |
Henrik Wulff | Novo Nordisk AS | 54 | |
Jerzy Gruhn | Novo Nordisk AS | 51 | |
Charles Wagner | Vertex Pharmaceuticals | 56 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |